[Gliflozins: Proteinuria Control and Nephroprotection].

Q4 Medicine
Simona Barbuto, Veronica Catalano, Marianna Pira, Giuseppe Cianciolo, Giorgia Comai, Irene Capelli, Francesco Tondolo, Federica Maritati, Gaetano La Manna
{"title":"[Gliflozins: Proteinuria Control and Nephroprotection].","authors":"Simona Barbuto, Veronica Catalano, Marianna Pira, Giuseppe Cianciolo, Giorgia Comai, Irene Capelli, Francesco Tondolo, Federica Maritati, Gaetano La Manna","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>In recent years, the prevalence of chronic kidney disease (CKD) has significantly increased, with an estimated 843.6 million individuals affected in 2017 [1]. This rise is closely linked to the growing incidence of risk factors such as diabetes mellitus and obesity. Patients with diabetic kidney disease (DKD), one of the most common complications of diabetes, are characterized by high cardiovascular morbidity and mortality. Recent evidence indicates that sodium-glucose cotransporter 2 inhibitors (SGLT2i) play a crucial role in reducing the progression of both DKD and CKD, thanks to its nephroprotective and cardioprotective effects. SGLT2i work by decreasing glomerular hyperfiltration, improving tubulo-glomerular feedback, and reducing blood glucose levels.</p>","PeriodicalId":12553,"journal":{"name":"Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia","volume":"41 Suppl 83","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

In recent years, the prevalence of chronic kidney disease (CKD) has significantly increased, with an estimated 843.6 million individuals affected in 2017 [1]. This rise is closely linked to the growing incidence of risk factors such as diabetes mellitus and obesity. Patients with diabetic kidney disease (DKD), one of the most common complications of diabetes, are characterized by high cardiovascular morbidity and mortality. Recent evidence indicates that sodium-glucose cotransporter 2 inhibitors (SGLT2i) play a crucial role in reducing the progression of both DKD and CKD, thanks to its nephroprotective and cardioprotective effects. SGLT2i work by decreasing glomerular hyperfiltration, improving tubulo-glomerular feedback, and reducing blood glucose levels.

[格列吡嗪:控制蛋白尿和保护肾脏]。
近年来,慢性肾脏病(CKD)的发病率大幅上升,2017 年估计有 8.436 亿人受到影响[1]。这一增长与糖尿病和肥胖等风险因素的发病率不断增加密切相关。糖尿病肾病(DKD)是糖尿病最常见的并发症之一,患者的心血管疾病发病率和死亡率都很高。最近的证据表明,钠-葡萄糖共转运体 2 抑制剂(SGLT2i)具有保护肾脏和心脏的作用,在减少糖尿病肾病和慢性肾脏病的进展方面发挥着至关重要的作用。SGLT2i 通过降低肾小球高滤过率、改善肾小管-肾小球反馈和降低血糖水平发挥作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.70
自引率
0.00%
发文量
62
期刊介绍: Il Giornale Italiano di Nefrologia (GIN) è la rivista di educazione continua della Società Italiana di Nefrologia SIN ed è pubblicato bimestralmente. E" il più autorevole organo di informazione nefrologia disponibile a livello nazionale. Il giornale Italiano di Nefrologia offre la più aggiornata informazione medico-scientifica rivolta al nefrologo sotto forma di rassegne, casi clinici e articoli finalizzati all’Educazione Continua in Medicina, oltre ai notiziari ed agli atti dei congressi di questa prestigiosa Società Scientifica
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信